Archives March 2026

LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerse^TM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale.

As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerse^TM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems.

AppIQ — Modernize Legacy Applications, Faster

AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously required weeks of reverse engineering can now be completed in days, significantly reducing modernization risk and cost.

AgentIQ — Orchestrate AI Agents Across Software Delivery

AgentIQ provides a unified platform to deploy, govern, and orchestrate AI agents across the software delivery lifecycle, with ready‑to‑use agents, no‑code setup, and enterprise‑grade security—enabling production‑ready AI adoption across engineering teams.

FusionIQ — Accelerate Speed to Market with Assured Quality

FusionIQ accelerates enterprise test automation across the software testing lifecycle, from requirement understanding and test design to automation scripting, test data management, and continuous optimization by embedding AIdriven monitoring and feedback into testing workflows.

Together, AppIQ, AgentIQ and FusionIQ deliver 40–50% reduction in engineering effort across the software development lifecycle — from legacy modernization and AI-driven delivery to quality engineering — while accelerating time-to-market and lowering ongoing operational costs.

“BlueVerse^TM Tech reflects a fundamental shift in how engineering organizations create value with AI. By embedding AI across modernization, delivery orchestration, and quality engineering, we are helping clients reduce complexity, improve predictability, and move faster with confidence—turning AI from experimentation into measurable business advantage at scale,” said Gururaj Deshpande, Chief Delivery Officer, LTM.

Availability

AppIQ, AgentIQ and FusionIQ are available globally as part of LTM’s BlueVerse^TM Tech and AI‑Led Engineering offerings, through platform adoption, managed services, and transformation‑led engagements. To learn more, visit www.ltm.com/blueverse.

ACT Fibernet, one of India’s leading broadband service providers, has bagged a prestigious double win at the ET Telecom Awards 2026, clinching honours in the Best Technology-Led Telecom Campaign category and the ‘AI for All’ Innovation Pioneer category. The recognition underscores ACT Fibernet’s commitment to driving technological excellence and democratising AI-powered experiences for its customers across India through its AI-powered Wi-Fi, i.e., ACTSmartWifi.

The ET Telecom Awards, hosted by The Economic Times, are widely regarded as one of the most credible benchmarks of innovation and leadership in India’s telecommunications industry. Being recognised across two distinct categories reflects the breadth and depth of ACT Fibernet’s technology-first approach to connectivity.

The Best Technology-Led Telecom Campaign award comes as a testament to ACT Fibernet’s ability to translate complex technological capabilities into compelling, consumer-centric narratives that resonate at scale. The ‘AI for All’ Innovation Pioneer award acknowledges the company’s strides in integrating artificial intelligence into its network infrastructure and customer experience platforms, making intelligent connectivity a reality for millions of users.

Commenting on the twin win, Ravi Karthik, Chief Growth Officer ACT Fibernet, said, “We have had this vision of building superior Wi-Fi experiences for our customers for over 3 years and have been working at it through proprietary technology. It is a great feeling to be recognised not just for the industry first technology and AI pioneer in telecom but also for taking this technology story to consumers through our ACTSMARTWIFI campaign.

For us at ACT, we constantly innovate to provide the best technological and customer experience that enable digital possibilities for every home and business. We are committed to continue investing and growing our capabilities towards the same.”

With a growing fiber network across India, ACT Fibernet continues to invest in future-ready technologies that elevate the standard of digital living in India.

In a world where travel inspiration often lives on screens, PANDA-MONIUM, the collaboration between SOCIAL and the Hong Kong Tourism Board (HKTB), reimagined how destinations can show up in everyday life. More than a campaign, it was a month-long cultural takeover which started in September 2025 and transformed 45 SOCIAL outlets into immersive panda-inspired zones, bringing Hong Kong’s cultural narrative directly into neighbourhood cafés across India.

Designed as a 30-day, multi-city experience, PANDA-MONIUM converted SOCIAL’s spaces across Mumbai, Delhi-NCR, Bangalore, Hyderabad, and Pune into playful “Panda Zones”, featuring 50–100 life-sized panda installations at flagship outlets, themed décor, and a limited-edition Hong Kong-inspired menu. The campaign saw over 2 lac guests interact with the installations, Hong Kong-inspired beverages and more, turning everyday visits into moments of cultural discovery and participation.

When PANDA-MONIUM arrived at SOCIAL, it did something unusual for destination marketing: it stepped out of traditional travel campaigns and into neighbourhood hangouts. Instead of waiting for travellers to seek out a destination, it brought Hong Kong into spaces people already inhabit: cafés, conversations, and community tables.

The campaign blended physical immersion with digital curiosity. Larger-than-life panda installations, and Hong Kong–inspired cocktails and mocktails created a multi-sensory experience that sparked conversation across tables and social feeds alike. In flagship locations such as Khar SOCIAL, Connaught Place SOCIAL, Bellandur SOCIAL, and Mindspace SOCIAL, immersive Panda Tourism Zones encouraged guests to explore, click, and share their encounters.

What made the campaign particularly powerful was its ability to integrate travel inspiration into the rhythm of everyday life. SOCIAL’s guests didn’t encounter Hong Kong through brochures or travel ads, but through trivia cards with every order, interactive storytelling, themed beverages, and experiential workshops that introduced them to the city’s culture in unexpected ways.

At the heart of PANDA-MONIUM was a celebration of Hong Kong’s most beloved cultural ambassadors, its giant pandas. From Ying Ying and Le Le at Ocean Park to the arrival of An An and Ke Ke and the birth of Hong Kong’s first panda twins, the campaign tapped into the global fascination with these iconic animals to create an emotional and playful bridge between India and Hong Kong.

Reflecting on the campaign, Puneet Kumar, Director, South Asia, Hong Kong Tourism Board, said: “PANDA-MONIUM was about bringing the spirit of Hong Kong to India in a way that felt joyful and immersive. Pandas are an important part of Hong Kong’s story, symbolising friendship and conservation, and this campaign allowed us to share that story with a new generation of travellers. By collaborating with SOCIAL, we were able to engage audiences in spaces where culture, food, and community naturally intersect.”

From panda-filled décor and experiential installations to limited-edition beverages like Harbour Martini, Lan Kwai Fizz, Temple Street Heat, and Junk Boat Breeze, the campaign created a playful gateway to Hong Kong’s culture and nightlife, one sip and selfie at a time.

Today, PANDA-MONIUM is remembered not just as a campaign but as a case study in how destinations can move beyond traditional tourism promotion and become part of everyday cultural experiences. By turning neighbourhood cafés into windows to the world, SOCIAL and HKTB demonstrated that sometimes the best way to inspire travel is to let people experience a small slice of the destination before they ever board a plane.

Global IT services provider FPT has been positioned as a Major Contender in the Everest Group Application Development Services for AI Applications PEAK Matrix® Assessment 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322476597/en/

The assessment evaluates 35 application development service providers on their ability to build and scale AI-powered enterprise applications, with emphasis on innovation, ecosystem partnerships, and AI talent readiness.

The recognition reflects FPT’s end-to-end AI capabilities, spanning strategy, solution design, application development, integration, and deployment of production-grade AI systems. At the center of this capability is IvyHub, FPT’s unified agentic AI platform built to help enterprises design, deploy, and govern AI agents at scale. IvyHub brings together conversational AI and workflow automation in one platform, so chatbots, virtual assistants, and voice agents can operate reliably across complex, multi-system environments, while enterprise AI agents can move beyond answering questions to executing tasks, coordinating processes, and supporting collaboration across teams.

Positioned for industries such as banking, finance, and retail, IvyHub is designed to deliver scalable, intelligent automation with strong enterprise integration. It can also be deployed natively on NVIDIA infrastructure, providing performance and compatibility advantages for organizations looking to operationalize AI agents across their ecosystems.

“AI is moving from copilots to agents that can execute workflows securely and reliably. Our focus is to help enterprises integrate AI agents into production with the right guardrails, deep domain context, and tight integration into core applications. FPT will continue investing in AI-powered tools and solutions, and responsible deployment frameworks to help organizations accelerate time to value and scale AI adoption with confidence,” said Dao Duy Cuong, FPT Software Executive Vice President and Chief Digital & Technology Officer, FPT Corporation.

AI remains central to FPT’s growth strategy. The company launched FleziPT, its AI-first platform designed to deliver end-to-end, customized AI-enabled transformation solutions, backed by an AI-augmented workforce. FPT also partners with NVIDIA to establish FPT AI Factories in Japan and Vietnam, which are recognized among the world’s top 40 fastest supercomputers in the latest TOP500 ranking. The company also collaborates with Mila Institute on AI research, and is a founding member of the AI Alliance led by IBM and Meta. These initiatives reinforce FPT’s leadership in AI development and support its broader goal of helping enterprises adopt and scale intelligent solutions.

About FPT Corporation

FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam and operates in three core sectors: Technology, Telecommunications, and Education. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. As an AI-first company, FPT is committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises. FPT focuses on three critical transformations: Digital Transformation, Intelligence Transformation, and Green Transformation. In 2025, FPT reported a total revenue of USD 2.66 billion and a workforce of over 54,000 employees across its core businesses.

For more information about FPT’s global IT services, please visit https://fptsoftware.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260322476597/en/

• The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony^1-3
• The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction^1,2
• This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty⁴

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.^1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.^1-3

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/

With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.^4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.^1,4,6,7

The volume of the temples can diminish with age, which can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance.^3,8,9 These facial changes can be accelerated in people undergoing medication-driven weight loss, a phenomenon which has increased rapidly in recent years resulting in a growing area of aesthetic need.^3,8,9 Galderma is spearheading efforts to address these concerns, including with this latest approval for Restylane Contour, which provides a new option for increasing volume in the temples to help restore balance for a more refreshed, youthful look.^1-3 With a dual-layer patent-pending technique leveraging both needle and cannula, Restylane Contour enables healthcare professionals to provide precise, customized, and safe product placement in line with each patient’s aesthetic goals.^1-3 Restylane Contour is powered by OBT™/XpresHAn™ technology, which integrates into the skin and balances support and flexibility, to provide long-lasting, natural-looking results that move with facial expressions.^1-3,6

The approval is based on clinical results showing that Restylane Contour improved temple hollowing compared with no treatment at three months, with results lasting for up to 18 months, and high investigator and patient (clinical trial participant) satisfaction:^1,2

• Efficacy:
  • 91% of patients were considered treatment responders at three months and over 85% were considered treatment responders up to 18 months after initial treatment^1,2
  • Clinical investigators rated 100% of patients as having improved from baseline at three months, with 98% at six months and 89% at 18 months^1,2
• Patient satisfaction:
  • Over 70% of patients felt they looked younger, less tired, and more refreshed 18 months after treatment, and 85% felt their temples looked natural at Month 18^1,2
  • Over 84% of patients were satisfied with their temples for a full 18 months as assessed by the FACE-Q patient-reported outcome tool^1,2
  • 99% of investigators felt the results were natural looking three months after treatment^1,2
• Safety:
  • All treatment-related adverse events were mild to moderate, with no serious events^1,2

With over 30 years of innovation and more than 77 million treatments administered worldwide, Restylane remains highly relevant in addressing some of today’s most significant aesthetic trends and needs, from changes following medication-driven weight loss to growing concerns related to menopause and skin health.^10-14 As patient expectations shift toward more effortless, always-on rejuvenation, Galderma’s new ‘Wake Up To Restylane’ campaign positions Restylane as an everyday natural beauty ally for the face and body, highlighting Galderma’s commitment to meeting emerging needs. Focused on the growing desire for natural, authentic results, the campaign underscores Restylane’s ability to deliver personalized outcomes that move naturally with expression, helping people look refreshed and feel confident in their skin.^6,7,14,15

*Restylane Contour is known as Restylane Volyme™ in countries outside of the U.S.
**Spokesperson is a paid Galderma consultant

Important safety information
Restylane Contour is indicated for cheek augmentation and the correction of midface contour deficiencies in patients over the age of 21. Restylane Contour is also indicated for correction of temple hollowing in patients over the age of 21.

Restylane Contour contains traces of gram-positive bacterial protein and is contraindicated for patients with allergies to such material or for patients with severe allergies that have required in- hospital treatment. Restylane Contour should not be used by people with bleeding disorders, with hypersensitivity to amide-type local anesthetics, such as lidocaine, or by women who are pregnant or breastfeeding.

The most common side effects include bruising, redness, swelling, pain, tenderness, and itching at the injection site. Use at the site of skin sores, pimples, rashes, hives, cysts, or infection should be postponed until healing is complete. The safety or effectiveness of treatment in areas other than the cheek, midface or temple has not been established in controlled clinical studies.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers, and cases have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own. Serious but rare side effects include delayed onset infections, recurrence of herpetic eruptions, superficial necrosis, and scarring at the injection site. Do not implant into blood vessels. Use with caution in patients recently treated with anticoagulant or platelet inhibitors to avoid bleeding and bruising.

Restylane Contour is only available through a licensed practitioner. Complete Instructions for Use are available at www.RestylaneUSA.com.

About the Restylane portfolio
Restylane hyaluronic acid injectables are designed differently to go beyond volumizing for natural-looking results.^1,14,16 Our hyaluronic acid is exceptionally pure and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.^17-19 Restylane’s unique technologies, NASHA HD™, NASHA™ and OBT™/XpresHAn™, are meaningfully designed to mimic the diverse range of facial structures and skin layers.^5,14,16,20 With the highest G’ and highest flexibility, Restylane can provide structural support, natural expressions and a healthy glow.^6,16,19-23 Trusted for almost three decades, our hyaluronic acid gels work in sync with your skin for natural looking results.^14,24,25

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Restylane® Contour™. Instructions for use. Available online. Accessed March 2026
2. Galderma Laboratories, L.P. Data on file. MA-63365 Study Report. 2025
3. Galderma. Data on file. Restylane Contour temple investigator closeout meeting executive summary. 2025
4. Restylane® Lyft™. Instructions for Use. Available online. Accessed March 2026
5. Galderma Data on file. MA-56724. X-strain and G’ including Shaype
6. Öhrlund Å, et al. Differentiation of NASHA and OBT hyaluronic acid gels according to strength, flexibility, and associated clinical significance. J Drugs Dermatol. 2024;23(1):1332–1336
7. Belmontesi M, et al. Injectable non-animal stabilized hyaluronic acid as a skin quality booster: An expert panel consensus. J Drugs Dermatol. 2018;17(1):83–88
8. Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719- 72
9. Qin J. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98
10. Galderma. Data on file. MA-57232 [Updated]. 77 Million treated
11. Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis
12. Fabi SG, et al. The potential role of biostimulators/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS 2026; January 29-31, 2026; France
13. Lorenc ZP, et al. Synergistic efficacy and safety of poly-L-lactic acid biostimulator and hyaluronic acid filler for facial fullness post weight loss due to glucagon-like peptide-1 receptor agonist medication. Presented at the ASDS 2025 Annual Meeting; November 13-16; United States
14. Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco
15. Galderma. Data on file. Global report: Aesthetics treatments and hyaluronic acid injectables. Consumers & HCPs. 2025
16. Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021
17. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179.
18. Galderma. Data on file. MA-58650. Degree of modification of HA fillers
19. Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312
20. Nikolis A, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? Aesthet Surg J Open Forum. 2020;2(1):1–12
21. Bromée T, et al. A new hyaluronic acid injectable, HASHA, sets new G-prime standards. Abstract presented at AMWC 2025; Mar 27-29, 2025; Monaco
22. Narins RS, et al. Persistence of nasolabial fold correction with a HA dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37: 644-650
23. Talarico S, et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18-month open multicenter study. Dermatol Surg. 2015;41: 1361–1369
24. Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3): 738-746
25. Philip-Dormston WG, Schuster B, and Podda M. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7): 1600-1606

View source version on businesswire.com: https://www.businesswire.com/news/home/20260322108467/en/